Andrea Necchi, MD, on KEYNOTE-057: Pembrolizumab Monotherapy May Benefit Some Patients With Bladder Cancer

Posted: Friday, February 24, 2023

Andrea Necchi, MD, of Italy’s Vita-Salute San Raffaele University and the IRCCS San Raffaele Hospital and Scientific Institute, discusses the possible ramifications of recent findings from the KEYNOTE-057 trial on a novel systemic therapy for papillary high-risk non–muscle-invasive bladder cancer. The data suggest that patients whose disease does not respond to bacillus Calmette-Guérin or who declined or were ineligible for a radical cystectomy may benefit from pembrolizumab monotherapy, which showed antitumor activity after about 45 months of follow-up.

---